One customer — 10% of revenue (For the nine months ended September 30, 2026)
“For the nine months ended September 30, 2026, one customer accounted for more than 10% of our total revenue.”
2 customers — 10% of revenue (For the three months ended September 30, 2026)
“For the three months ended September 30, 2026, two customers each accounted for more than 10% of our total revenue.”
2 customers — 10% of receivables (As of September 30, 2026)
“As of September 30, 2026, two customers each accounted for more than 10% of our accounts receivable.”
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Butterfly says semiconductor licensing revenue could dwarf point-of-care ultrasound over the next couple of years. The company also reports a starting community-care revenue stream and growing three- or five-year enterprise software contracts.
Butterfly Network reported Q3 2026 revenue of $32.6 million, up 52% year-over-year, and raised full-year revenue guidance to $123 million-$126 million. Full-year adjusted EBITDA loss guidance improved to $12 million-$15 million, while cash and cash equivalents ended the quarter at $122 million.
On October 29, 2026, Butterfly Network, Inc. registered an automatic shelf and a sales agreement for up to $150,000,000 of Class A common stock, alongside other securities.
Butterfly’s software and other services revenue increased by $10.0 million, or 144.8%, for the three months ended September 30, 2026, and the category represented 52.1% of revenue.
Butterfly Network reported third-quarter revenue of $32.6 million, up 52% year over year, and a record 73% gross margin, and raised Fiscal Year 2026 revenue guidance to $123 million to $126 million with adjusted EBITDA loss guidance of $12 million to $15 million.
Useful current figures from the complete screener profile.
* Q4 derived as the full year minus Q1 to Q3.
TL;DR. Butterfly delivered 52% Q3 revenue growth, more than 1,000% Embedded growth, record 73% gross margin, improved adjusted EBITDA and net loss, and raised full-year revenue and adjusted EBITDA guidance; enterprise, FedRAMP and Home & Community Care also advanced. International revenue declined, operating expenses increased, Embedded revenue may remain uneven, the ATM program creates potential dilution, competition is intensifying, and external risks remain.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Illustrative technical + ownership context — a signal mix, not investment advice.
| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted EBITDA non-GAAP | -7.51M | Six months ended June 30, 2026 | — |
GAAP → non-GAAP reconciliationAdjusted net loss -2.24M (the result of another reconciliation in this filing)
-1.08M Interest income
+282K Interest expense
+0K Provision for income taxes
+1.66M Depreciation and amortization
= Adjusted EBITDA -1.38M
|
|||
| Adjusted EBITDA loss non-GAAP | $1.4M | Q2 2026 | — |
| Adjusted EPS non-GAAP | -$0.04 | Six months ended June 30, 2026 | — |
| Adjusted gross margin non-GAAP | 70.3% | Six months ended June 30, 2026 | — |
| Adjusted gross profit non-GAAP | 41.57M | Six months ended June 30, 2026 | — |
GAAP → non-GAAP reconciliationGAAP Gross profit 23.29M
+0K Write-downs and write-offs of inventories
= Adjusted gross profit 23.29M
|
|||
| Adjusted net loss non-GAAP | -9.28M | Six months ended June 30, 2026 | — |
GAAP → non-GAAP reconciliationGAAP Net loss -12.91M
+7.04M Stock-based compensation
+0K Write-downs and write-offs of inventories
+0K Change in fair value of warrant liabilities
+3.59M Other
+43K Other expense (income), net
= Adjusted net loss -2.24M
|
|||
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
BFLY
this stock
Butterfly Network, Inc.
|
$1.63B | +60.0% | +19.0% | — | 12.8% |
|
ABT
Abbott Laboratories
|
$187.95B | -13.4% | +5.7% | 40.5 | 1.1% |
|
MDT
Medtronic plc
|
$131.57B | +7.1% | +8.4% | 25.3 | 1.8% |
|
SYK
Stryker Corp
|
$117.88B | -11.9% | +11.2% | 33.0 | 1.7% |
|
BSX
Boston Scientific Corp
|
$64.27B | -53.5% | +12.5% | 18.8 | 2.4% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
Butterfly says semiconductor licensing revenue could dwarf point-of-care ultrasound over the next couple of years. The company also reports a starting community-care revenue stream and growing three- or five-year enterprise software contracts.
View| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| BFLY | -4.6% | -16.1% | +33.9% | -4.9% | +60.0% |
| SPY | +2.6% | -1.2% | +0.5% | -0.2% | +10.6% |
| vs SPY | -7.1% | -15.0% | +33.4% | -4.7% | +49.4% |
